After Hours Summary: FNSR +13%, ZUMZ +4% following earnings/guidance/SSS, LPTN +28% on merger news... VMEM -25% following earnings/guidance, WMB -3% after Enterprise drops pursuitAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: FNSR +12.8%, ZUMZ +3.6% (also reports August comps fell 1.1% vs. -10.7% last year), DLTH +2.9%, EGAN +2.9% (thinly traded)
Companies trading higher in after hours in reaction to news: LPTN +28.1% (Lpath announces definitive merger agreement with Apollo Endosurgery), LOCO +6.5% (to join the S&P SmallCap 600), SWFT +5.1% (Swift Transportation CEO Jerry Moyes to retire, COO Richard Stocking has been unanimously appointed by the Board as CEO), OCLR +4.8% (Kopp Family Office discloses 6.9% passive stake; also FNSR sympathy), LITE +2.7% (FNSR sympathy), WSM +1.6% (RH sympathy), HZNP +0.7% (light volume; amends commercial supply agreement with Bio-Technology General)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: VMEM -25%, PPHM -9.3%, VNCE -7.4% (light volume), XTLY -3.5%
Companies trading lower in after hours in reaction to news: LNTH -10.3% (announces an underwritten public offering of 5.2 mln shares of common stock), NEP -4.1% (announces agreement to acquire indirect 24% interest in Desert Sunlight Investment Holdings, announces offering of common units), BAS -4% (after closing near highs - up 85% on the day), ETRM -2.8% (ticking lower, sends notice of special meeting to stockholders to seek approval for a reverse stock splitat a ratio of between 1-for-10 and 1-for 20), WMB -2.6% (Enterprise withdraws indication of interest in Williams Cos; Williams Cos will consolidate the number of Operating Areas within the co from five to three by early 2017, provides biz highlights) ESTE -2.3% (light volume - files for 12,081,740 share common stock offering by selling shareholders), WPZ -1% (on Enterprise / Williams Cos news) PDCE -0.9% (announces a concurrent underwritten public offering consisting of 6.5 mln shares of common stock & $100 mln convertible senior notes due 2021), VRX -0.2% (Allergan CEO on CNBC says not interested in acquiring Valeant, not looking at doing transformational M&A)